secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001493152-26-009689
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem reports FY2025 net sales $20.2M (+4% YoY), income from operations $3.4M vs loss $7.7M
--------------------------------------------------------------------------------

- Record net sales of $20.2M in FY2025, fifth consecutive year of growth; up 4% from $19.4M in FY2024.
- Income from operations of $3.4M in FY2025 vs loss of $7.7M in FY2024; net income of $0.3M vs net loss of $9.0M.
- Reduced total operating expenses by 38% to $16.8M, including gains from vendor settlement and royalty liability change.
- Q4 2025 net sales of $9.6M (+35% YoY); operating income of $3.3M vs loss of $1.0M; net income of $2.8M vs loss of $3.0M.
- Since Oct 2025: targeting 55-60% manufacturing cost reduction for PHEXX and SOLOSEC; UAE pricing certificates received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226009689/0001493152-26-009689-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315226009689/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009689

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer